Our latest
Press Releases & Updates

Latest press releases

Ikerian AG, Parent Company of RetinAI U.S. Inc. Announces Final Close of USD 6.18M (CHF 5.65M) Series A Extension Financing

Ikerian AG, Parent Company of RetinAI U.S. Inc. Announces Final Close of USD 6.18M (CHF 5.65M) Series A Extension Financing

RetinAI Discovery® platform and AI tools launched to improve decision workflows, referrals and patient management in Clinics for Ophthalmologists and Optometrists

Ikerian AG and RetinAI Inc. unveil RetinAI Discovery® for Clinics, revolutionizing eye care with AI-enhanced diagnostics and patient management for Ophthalmologists and Optometrists. This advanced platform streamlines clinical workflows and boosts patient engagement through innovative AI technology.

RetinAI Joins Forces with Stephen J. Ryan Initiative for Macular Research (RIMR) AMD Consortium to Forge a Global Retinal Imaging Initiative Targeting Research in AMD

RIMR members from around the world will now be able to connect through RetinAI’s cloud- based platform, RetinAI Discovery®, to facilitate a frictionless collaboration and derive insights on global AMD datasets, helping to advance research in this disease that is a leading cause of blindness in older individuals.

Joint Initiative to Precisely Target Patient Selection for PBM Therapy in Intermediate, Dry AMD Using RetinAI’s Discovery Platform

Discover how RetinAI's groundbreaking Discovery® platform and Gutblick's clinical expertise are joining forces to transform the future of eye care. Their collaboration focuses on harnessing AI technology for advanced research and clinical applications in managing Dry Age-related Macular Degeneration. This partnership signifies a leap forward in personalized treatment and care, setting new standards in ophthalmology.

Latest updates

Fully-automated atrophy segmentation in dry age-related macular degeneration in optical coherence tomography - Scientific Reports

RetinAI is thrilled to introduce our novel method for the segmentation of atrophy with performance matching human experts published in Scientific Reports and developed in collaboration with the Fondation Asile des aveugles, Hôpital ophtalmique Jules-Gonin in Lausanne. Congratulations to both teams for this success!

Full Article -

Authors: Yasmine Derradji, Agata Mosinska, Stefanos Apostolopoulos, Carlos Ciller, Sandro De Zanet & Irmela Mantel Widmer

Automatic Atrophy Progression Prediction in Age-Related Macular Degeneration in EURETINA 2021

We are happy to present our novel method for prediction of continuous atrophy growth for follow-up periods of 4 years and longer in this year's EURETINA 2021. Congratulations to our collaborators and team members for this great poster.

We enable for the first time the creation of atrophy risk maps, which present the risk of retinal regions being affected by the atrophy in the future.

Authors: Agata Mosinska, Anthony Gigon, Stefanos Apostolopoulos, Carlos Ciller, Irmela Mantel Widmer, Sandro De Zanet

RetinAI in Top 100 Swiss Startups for 2021

RetinAI is proud to be recognized as one of the TOP 100 Swiss Startups for 2021. Check out the ‘Hall of Fame’ on to see Retinai again in the list this year.

Huge thanks to everyone in the team, to our supporters, and to our partners for believing in us along the way and for supporting us to define the future of Digital Precision Medicine!

First Peer-reviewed Publication around the RAZORBILL Study

The very first peer-reviewed publication around the RAZORBILL study has been published in the British journal of Ophthalmology (BJO).

'Does real-time artificial intelligence-based visual pathology enhancement of three-dimensional optical coherence tomography scans optimise treatment decision in patients with nAMD? Rationale and design of the RAZORBILL study'

A first of its class international multi-center clinical study to assess the influence of automated 3D OCT scan enrichment with segmentation information on disease activity assessment in patients with nAMD treated with either brolucizumab, ranibizumab or aflibercept.

We are glad to be supporting this initiative together with a leading team of world renown ophthalmologists & Novartis!

Contact us for more informations! We are happy to hear from you!